Kuva Labs to Merge with Lisata Therapeutics

Kuva Labs Inc. entered into an agreement and plan of merger with Kuva Acquisition Corp. and Lisata Therapeutics, Inc., dated March 6, 2026, as shown in an SEC 8-K exhibit. The filing outlines an offer process and the mechanics of the merger, including closing and effective time.

The agreement also covers post-merger governance items such as the surviving corporation’s certificate of incorporation and bylaws, plus directors and officers. It further addresses how equity is handled, including conversion of securities, rollover shares, and treatment of equity awards and company warrants.